BioCryst Pharmaceuticals BCRX Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax
Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax.
The official record: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about BioCryst Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BioCryst Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- BioCryst Pharmaceuticals (BCRX) reported debt securities, available-for-sale, accumulated gross unrealized loss, before tax of $95K in Q1 2026.
- How has BioCryst Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax changed year-over-year?
- BioCryst Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax increased by 2275.0% year-over-year, from $4K to $95K.
- What is the long-term trend for BioCryst Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax?
- Over 3 years (2022 to 2025), BioCryst Pharmaceuticals's debt securities, available-for-sale, accumulated gross unrealized loss, before tax has grown at a -83.2% compound annual growth rate (CAGR), from $1.06M to $5K.